Z-Medica, LLC announces that they are supporting the Friends of Yale New Haven Children's Hosptial with a $10,000 contribution to this year's Annual Fund.
Read More
Z-Medica, LLC announces that QuikClot® Control+™ has been cleared for use by the US Food and Drug Administration (FDA) under the de novo classification process and is designated as a Class II medical device.
Z-Medica, LLC, announces today that they are supporting the Entrepreneurship Bootcamp for Veterans with Disabilities (EBV) program at the University of Connecticut (UConn) School of Business.
View All News Articles
The unpredictable nature of patient care requires a reliable way to achieve hemostasis.
Life is unpredictable – a bleeding injury can occur without warning and the ability to quickly control blood loss can make all the difference.
Trauma is a major cause of death and disability and the second most expensive healthcare problem in the United States. Approximately 40% of trauma-related deaths are due to bleeding or its consequences, establishing hemorrhage as the most common cause of preventable death in trauma.1
1. Curry N, Hopewell S, Doree C, Hyde C, Brohi K, Stanworth S. The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit Care . 2011;15(2):R92.
Used by many municipalities across the United States, QuikClot® hemostatic devices put life-saving technology into the hands of trained law enforcement officials.
After extensive testing by the United States Army Institute for Surgical Research (USAISR) and the Naval Medical Research Center (NMRC), the Committee on Tactical Combat Casualty Care (CoTCCC) chose QuikClot Combat Gauze®.
1. Tactical Combat Casualty Care Guidelines 2 June 2014. http://www.usaisr.amedd.army.mil/pdfs/TCCC_Guidelines_140602.pdf. Accessed March 25, 2015.
Our site includes links to third party sites in which the Z-Medica® Privacy Policy and Terms of Use do not apply. Please read the privacy policy for every third party website you visit.
Close Continue Close